DNA修复基因XRCC1基因多态性与乳腺癌临床病理参数的相关性

目的 :研究XRCC1基因Arg194Trp和Arg399Gln多态性与中国女性乳腺癌临床病理参数的关系,探讨其在乳腺癌预后中的潜在意义。 方法 :采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法,对250例原发性乳腺癌患者进行XRCC1基因Arg194Trp、Arg399Gln多态性分析,用Pearsonχ²检验分析基因型与临床病理特征的关系。 结果 :XRCC1基因Arg194Trp和Arg399Gln多态性与乳腺癌患者的月经状态、肿瘤大小、腋窝淋巴结转移、TNM分期、雌激素受体均无显著相关性(P>0.05)。但该多态位点与乳腺癌患者的孕激素受体(PR)状态和C-erbB2蛋白表达显著相关。携带194纯合突变型的患者PR阴性率(81.0%)显著高于携带194野生型和杂合型患者(55.4%),(P=0.034);携带399纯合突变型的患者C-erbB2蛋白表达阳性率(61.1%)显著高于携带399野生型和杂合型的患者(29.3%),(P=0.006)。 结论 :PR阴性和(或)C-erbB2高表达的乳腺癌患者常提示预后不良。XRCC1基因多态性与PR阴性或C-erbB2高表达显著相关,提示携带XRCC1纯合突变(194或399)乳腺癌患者可能预后不良。     

DNA复基因XRCC1基因多态性与乳腺癌临床病理参数的相关性

目的:研究XRCC1基因Arg194Trp和Arg399Gln多态性与中国女性乳腺癌临床病理参数的关系,探讨其在乳腺癌预后中的潜在意义.方法:采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法.对250例原发性乳腺癌患者进行XRCC1基因Arg194Trp、Arg399Gln多态性分析,用Pearson χ2检验分析基因型与临床病理特征的关系.结果:XRCC1基因Arg194Trp和Arg399Gln多态性与乳腺癌患者的月经状态、肿瘤大小、腋窝淋巴结转移、TNM分期、雌激素受体均无显著相关性(P＜0.05).但该多态位点与乳腺癌患者的孕激素受体(PR)状态和C-erbB2蛋白表达显著相关.携带194纯合突变型的患者PR阴性率(81.0%)显著高于携带194野生型和杂合型患者(55.4%),(P=0.034);携带399纯含突变型的患者C-erbB2蛋白表达阳性率(61.1%)显著高于携带399野生型和杂合型的患者(29.3%),(P=0.006).结论:PR阴性和(或)C-erbB2高表达的乳腺癌患者常提示预后不良.XRCC1基因多态性与PR阴性或C-erbB2高表达显著相关,提示携带XRCC1纯合突变(194或399)乳腺癌患者可能预后不良.     

XRCC2基因多态性与肺癌易感性关系的研究

目的：探讨中国北方人群中XRCC2基因C41657T、G4234C多态性与肺癌的关系。方法：应用PCR-RFLP方法检测199例肺癌患者和200例正常人的XRCC2 C41657T及G4234C多态位点，比较两组之间等位基因及基因型频率分布及其与肺癌的关系。结果：肺癌患者XRCC2 C41657T多态位点的CC、CT、TT基因型和C、T等位基因频率分布与健康对照组相比差异均无统计学意义（P〉0．05）。G4234C多态位点的GG、GC、CC基因型和G、C等位基因频率分布与健康对照组相比差异也均无统计学意义（P〉0．05）。两多态性位点联合分析显示，肺癌患者与健康对照组的4个单体型分布亦无统计学差异（P〉0．05）。以病理类型、吸烟状况和年龄进行分层分析显示，XRCC2 C41657T多态位点可能与腺鳞癌和不吸烟人群的肺癌发病风险相关；与C／C基因型相比，携带T等位基因的基因型（C／T＋T／T）可显著增加腺鳞癌的发病风险（OR为2．95，95％CI=1．15—7．59）；而C／T基因型可显著增加不吸烟组人群中肺癌的发病风险（OR为2．12，95％CI=1．05-4．27）。对于XRCC2 G4234C多态位点，与G／G基因型相比，G／C基因型和携带C等位基因的基因型（G／C＋C／C）可显著增加小细胞肺癌的发病风险（OR为2．82和2．82；95％CI=1．15～6．91和1．17～6．76）；G／C基因型或与C／C基因型相加可显著增加年龄≥60岁的人群中肺癌的发病风险（OR为2．29和2．37；95％CI=1．11—4．72和1．16—4．88）。结论：对于XRCC2 C41657T多态位点，携带T等位基因的基因型可能增加腺鳞癌的发病风险，C／T基因型可能增加不吸烟者患肺癌风险；XRCC2 G4234C多态位点，G／C基因型或携带C等位基因可能增加小细胞肺癌的发病风险和老年人（年龄≥60岁）患肺癌的风险。     

汉族晚期大肠癌ERCC1和XRCC1基因多态性与奥沙利铂化疗敏感相关性的研究

目的:探讨ERCC1Asn118Asn和XRCC1Arg399Gln多态性与中国汉族晚期大肠癌患者对奥沙利铂(Oxaliplatin,L-OHP)一线化疗临床效果的关系。方法:62例晚期大肠癌患者化疗前抽取静脉血并提取DNA,以RT-PCR法对ERCC1、XRCC1基因进行SNP分型。患者接受奥沙利铂为主的化疗方案化疗,比较不同基因型与化疗效果的关系。结果:ERCC1Asn118Asn基因突变频率为:C/C53.23%(33/62),C/T37.10%(23/62),T/T9.67%(6/62);XRCC1Arg399Gln基因突变频率为:G/G50.00%(31/62),G/A37.10%(23/62),A/A12.90%(8/62)。62例患者化疗2～3个周期后评价临床获益率为54.84%。ER-CC1基因Asn118Asn基因型C/C与C/T T/T在化疗获益组和化疗不敏感组中分布差异有统计学意义,χ2=6.289,P=0.021。XRCC1基因Arg399Gln基因型G/G与G/A A/A在化疗获益组和化疗不敏感组中分布差异也有统计学意义,χ2=6.513,P=0.021。两者联合多态性分析发现,同时携带ERCC1C/C和XRCC1G/G基因型患者化疗敏感性是同时携带ERCC1C/T T/T和XRCC1G/A A/A基因型患者的11.333倍,P=0.002。结论:ERCC1Asn118Asn、XRCC1Arg399Gln基因多态性与中国汉族晚期大肠癌患者接受奥沙利铂一线化疗后的临床效果有关。     

XRCC1和XRCC3单核苷酸多态性与晚期非小细胞肺癌铂类药物化疗疗效的相关性

背景与目的 DNA修复基因多态性预测铂类药物化疗敏感性对非小细胞肺癌(non-small cell lung cancer,NSCLC)个体化治疗具有重要意义.本研究旨在探讨X线修复交错互补基因1(X-ray repair cross complementing gene 1,XRCC1)和X线修复交错互补基因3(X-ray repair cross complementing gene 3,XRCC3)单核苷酸多态性与晚期NSCLC患者对铂类药物化疗疗效的关系.方法 采用PCR-RFLP方法检测130例以含铂方案化疗的晚期NSCLC患者外周血DNA中XRCC1 Arg194 Trp、Arg399 Gln和XRCC3 Thr241 Met基因多态性,分析其基因型与化疗疗效的关系.结果 130例晚期NSCLC患者采用含铂方案化疗2个周期后,化疗总有效率为33.8％.XRCC1 194和399基因多态性与铂类药物化疗敏感性相关,而XRCC3 241基因多态性与化疗敏感性无关(P=0.145).携带至少1个XRCC1 194 Trp等位基因者化疗有效率至少是携带Arg/Arg基因型患者的2.5倍(42.1％vs22.2％,OR=2.545,95％CI:1.159-5.590,P=0.020).携带XRCC1399 Arg/Arg基因型者的化疗有效率为45.5％,明显高于携带至少1个Gln等位基因者(21.9％)(OR=0.336,95％CI:0.156-0.722,P=0.005).XRCC1 194和399基因多态性之间存在联合作用,同时携带至少1个XRCC1 194 Trp等位基因和399 Arg/Arg基因型者的化疗有效率明显高于同时携带194 Arg/Arg和399 Arg/Gln基因型者(44.4％ vs 18.8％,OR=3.467,95％CI:1.223-9.782,P=0.019).XRCC1和XRCC3基因多态性在化疗敏感性方面存在一定的联合作用,携带至少1个XRCC1 194 Trp等位基因和399 Arg/Arg野生型基因同时又携带XRCC3 241 Thr/Met基因型者的化疗有效率明显高于其它基因型携带者.结论 XRCC1和XRCC3的多态联合可能与晚期NSCLC患者对铂类药物化疗疗效具有相关性.     

XRCC1单核苷酸多态性与鼻咽癌铂类化疗敏感度的相关性

目的 探讨鼻咽癌铂类化疗敏感度与X射线交错互补修复基因1 codon194和codon399单核苷酸多态性的相关性。方法 收集广西医科大学第四附属医院2012年9月1日至2013年12月31日鼻咽部肿物活检确诊为鼻咽癌患者资料,采用限制性片段长度多态性聚合酶链反应技术检测鼻咽癌患者外周血DNA XRCC1 codon194和codon399单核苷酸多态性。顺铂+氟尿嘧啶方案诱导化疗2周期后复查MRI,按照RECIST 1.1标准评价其化疗敏感度,分析单核苷酸多态性（Single nucleotide polymorphism,SNP）与化疗敏感度的关系。结果 XRCC1 codon399 Gln/Gln基因型携带者化疗敏感度为Arg/Arg基因型携带者的3.500倍（P＜0.05）。XRCC1 codon399不含Arg基因型（即Gln/Gln）携带者化疗敏感度为含Arg基因型（Arg/Arg 和 Arg/Gln）携带者的3.274倍,（P＜0.05）。携带XRCC1 codon194各基因型患者化疗敏感度之间差异无明显统计学意义（P＞0.05）。结论 XRCC1 codon399 单核苷酸多态性有可能成为鼻咽癌铂类化疗敏感度的预测因子。     

BER通路中XRCC1多位点单核苷酸多态性与新疆不同民族喉癌易感性相关性研究

背景与目的:影响肿瘤遗传易感性的修复基因主要存在修复通路碱基切除修复(base excision repair,BER)途径,而X射线交错互补修复基因1(X-ray repair cross complementing group 1,XRCC1)是BER通路中的核心基因。近几年,国内外开展了许多有关基因多态性和喉癌易感性的研究。探讨BER通路DNA修复基因XRCC1多位点单核甘酸多态性与新疆不同民族喉癌易感性关系。方法:采用患者组与对照组的研究方法,选择58例喉癌(经病理证实为鳞状细胞癌)患者和120名体检正常的健康人对照,应用Multiplex SNa Pshot技术检测DNA碱基切除修复基因XRCC1的Gln632Gln(rs3547)、Arg399Gln(rs25487)、Arg280His(rs25489)、Arg194Trp(rs1799782)位点单核苷酸多态在患者组和正常对照组中的分布情况。结果:喉癌患者组中XRCC1Arg280His(rs25489)C/T(杂合型)及T/T(突变型)基因型的比例与对照组比较差异无统计学意义(P>0.05)。喉癌患者组中XRCC1的其余3个位点Gln632Gln(rs3547)C/T(杂合型)及T/T(突变型)基因型、Arg399Gln(rs25487)C/T(杂合型)及T/T(突变型)基因型、Arg194Trp(rs1799782)G/A(杂合型)及A/A(突变型)基因型的比例明显高于对照组(P<0.01)。其中汉、维、哈3个民族患者组Gln632Gln(rs3547)C/T(杂合型)及T/T(突变型)基因型、Arg399Gln(rs25487)C/T(杂合型)及T/T(突变型)基因型、Arg194Trp(rs1799782)G/A(杂合型)及A/A(突变型)基因型比例显著高于对照组(P<0.05),携带(rs3547)C/T及T/T基因型、(rs25487)C/T及T/T基因型、(rs1799782)G/A及A/A基因型个体较携带XRCC1(rs3547)C/C基因型、(rs25487)C/C基因型、(rs1799782)G/G基因型的个体患喉鳞状细胞癌的风险升高了分别为0.96倍、1.74倍、1.39倍;1.47倍、1.32倍、0.77倍,1.49倍、1.51倍、1.56倍。结论:汉、维、哈3个民族的XRCC1 Gln632Gln、Arg399Gln、Arg280His、Arg194Trp位点的单核苷酸多态性可能与喉癌遗传性有关联且有差异,XRCC1基因中的Gln632Gln、Arg399Gln、Arg194Trp位点的突变将导致喉癌的发病风险升高。而XRCC1基因中的Arg280His位点突变与喉癌发病的差异无统计学意义,可能该位点的突变与喉癌发病无关。     

XRCC1基因多态性与淋巴瘤发病风险的Meta分析

 目的运用Meta分析的方法综合评价DNA修复基因（X-ray repair cross-complementing group 1,XRCC1)的多 态性与淋巴瘤发病风险的关系。方法计算机检索PubMed、EMbase、中国期刊全文数据库、维普中文科技期刊数据库 、中国生物医学文献数据库,同时手工检索所有纳入文献的参考文献,收集截止到2010年2月关于XRCC1基因多态性 与淋巴瘤发病风险的病例对照研究,由两名研究者独立按照纳入标准筛选文献、提取资料并交叉核对,统计分析采 用RevMan5.0软件进行。结果共纳入11个病例对照研究,包括4 569例患者和5 746例对照。Meta分析结果显示： XRCC1 codon 399 基因型Gln/Gln、Arg/Gln和Gln/Gln+Arg/Gln与野生型Arg/Arg相比,频率差异均无统计学意义（ Gln/Gln vs. Arg/Arg:OR=1.04,95%CI［0.87,1.25］;Arg/Gln vs.Arg/Arg:OR=1.26,95%CI ［0.95,1.66］;Gln/Gln+Arg/Gln vs.Arg/Arg:OR=1.02,95%CI ［0.91,1.13］）,Gln/Gln+Arg/Gln基因型则有可 能增加霍奇金淋巴瘤的发病风险（OR=1.31,95%CI［1.02,1.69］）,XRCC1 codon280和XRCC1 codon 194的基因多 态性在患者和对照组之间的差异无统计学意义（XRCC1 codon280 His/His+Arg/His vs.Arg/Arg:OR=0.97,95%CI ［0.69,1.38］;XRCC1 codon 194 Trp/Trp+Arg/Trp vs.Arg/Arg:OR=1.01,95%CI［0.78,1.32］）。结论DNA修复 基因XRCC1的基因多态性与非霍奇金淋巴瘤发病风险没有相关性,codon399位点的Gln/Gln+Arg/Gln基因型则有可能 增加霍奇金淋巴瘤的发病风险。     

XRCC1单核苷酸多态性与鼻咽癌患者晚期放射性损伤的相关性

目的分析XRCC1 Codon399单核苷酸多态性与鼻咽癌患者正常组织晚期放射性损伤的相关性。方法经病理学检查确诊的60例鼻咽癌患者,放疗前提取全血基因组DNA,进行PCR扩增及LDP连接检测反应扩增,得出XRCC1 Codon399的3种基因型。随访至放疗结束后3个月,对晚期放射性损伤进行评价,比较XRCC1 Codon399不同基因型与正常组织晚期放射性损伤的相关性。结果 60例患者中,XRCC1 Codon399 Gln/Gln基因型6例,Arg/Gln基因型21例,Arg/Arg基因型33例,不同性别之间无明显差异。Gln/Gln基因型者1、2、3级皮肤晚期放射性损伤发生率分别为33.3%、66.7%、0,Arg/Gln基因型者为52.4%、42.9%、4.7%,Arg/Arg基因型者为63.6%、36.4%、0;Gln/Gln基因型患者1、2、3级皮下组织晚期放射性损伤发生率分别为33.3%、66.7%、0,Arg/Gln基因型者为38.1%、57.2%、4.7%,Arg/Arg基因型者为42.4%、57.6%、0;Gln/Gln基因型患者1、2、3级黏膜晚期放射性损伤发生率分别为100.0%、0、0,Arg/Gln基因型者分别为80.9%、14.3%4.7%,Arg/Arg基因型者分别为93.9%、6.1%、0;Gln/Gln基因型患者1、2、3级涎腺晚期放射性损伤发生率分别为100.0%、0、0,Arg/Gln基因型者分别为80.9%、14.3%、4.7%,Arg/Arg基因型者分别为93.9%、6.1%、0。经统计分析,不同基因型患者间晚期放射性损伤发生率无明显差异（P〉0.05）。结论 XRCC1 Co-don399单核苷酸多态性与鼻咽癌患者皮肤、皮下组织、黏膜、涎腺晚期放射性损伤程度无明显相关性,尚不能将其应用于对鼻咽癌患者正常组织晚期放射性损伤程度的预测。     

XRCC1多态性与非吸烟女性肺腺癌易感性的关系

背景与目的XRCC1是一种DNA损伤修复基因，其单核苷酸多态性异常是导致DNA修复能力个体差异的重要原因，可能导致个体患肺癌的危险升高。本研究的目的是探讨XRCC1单核苷酸多态性与非吸烟女性肺腺癌易感性的关系。方法采用以医院患者为基础的病例对照研究方法，研究对象包括非吸烟女性肺腺癌患者126例和同期其它肺部疾病对照126例。以聚合酶链反应一限制性片段长度多态性方法分析XRCC1基因Arg399Gln多态性，比较不同基因型与非吸烟女性肺腺癌的关系，并探讨油烟暴露与基因多态交互作用对患癌风险的影响。结果与携带399Arg／Arg基因型者比较，携带399Gln／Gln基因型者患肺腺癌的风险是其8．695倍（95％CI为3．343～22．614）。携带等位基因399Gln又有油烟暴露的个体患肺腺癌的风险明显增高，校正的比值比为5．21（95％CI为1．85～14．70，P〈0．001）。结论XRCC1基因Arg399 Gln多态性可能是非吸烟女性肺腺癌的遗传易感因素。     

A Meta-Analysis for Association of XRCC1, XRCC2 and XRCC3 Polymorphisms with Susceptibility to Thyroid Cancer

Background: We conducted a comprehensive meta-analysis to explore the association of polymorphisms at XRCC1, XRCC2 and XRCC3 genes with susceptibility to thyroid cancer (TC). Methods: We searched PubMed, EMBASE, Web of Science, and CNKI for relevant available studies. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of the associations. Results: A total of 67 studies including 17 studies with 6,806 cases and 5,229 controls on XRCC1 Arg399Gln, 13 studies with 3,234 cases and 4,807 controls on XRCC1 Arg280His, 13 studies with 2,956 cases and 3,860 controls on XRCC1 Arg194Trp, five studies with 1,287 cases and 1,422 controls on XRCC2 Arg188His, 13 studies with 2,488 cases and 3,586 controls on XRCC3 Thr241Met, and six studies with 1,828 cases and 2,060 controls on XRCC3 IVS5-14 polymorphism were selected. Polled data revealed that the XRCC1 Arg399Gln, Arg280His, Arg194Trp, XRCC2 Arg188His and XRCC3 Thr241Met and IVS5-14 polymorphisms were not significantly associated with an increased risk of TC. Stratified analyses by ethnicity showed that the XRCC1 Arg399Gln polymorphism was associated with TC risk in Caucasians, but not in Asians. Conclusions: Our meta-analysis indicated that the XRCC1 Arg399Gln, Arg280His, Arg194Trp, XRCC2 Arg188His, XRCC3 Thr241Met and IVS5-14 polymorphisms were not associated with risk of TC in the global population.  Further well-designed investigations with large sample sizes are required to confirm our results.     

DNA修复基因XRCC1多态性与肺癌易感性的关系

目的:研究碱基切除修复基因XRCC1多态性与肺癌易感性的关系。方法:采用病例-对照研究,收集太原市原发性肺癌患者111例为病例组,同时随机抽取210名健康居民作为对照组,并进行流行病学调查。应用PCR-RFLP方法分析由内切酶MspI识别XRCC1基因Arg399Gln位点的多态性,比较不同基因型与肺癌易感性的关系,以及基因多态性与吸烟之间对肺癌易感性的交互作用。结果:XRCC1密码子399杂合基因型Arg/Gln可能对鳞癌有较弱的保护效应,并可能降低吸烟者患肺癌的危险性。而纯合突变基因型Gln/Gln与和吸烟的存在协同作用可显著提高肺癌的危险度。结论:碱基切除修复基因XRCC1密码子399的多态性可能会对肺癌易感性产生影响,并可能与吸烟量之间存在一定的协同作用。     

Correlation between Selected XRCC2, XRCC3 and RAD51 Gene Polymorphisms and Primary Breast Cancer in Women in Pakistan

Genetic polymorphisms in homologous recombination repair genes cause an abnormal development ofcancerous cells. In the present study we evaluated the possibility of breast cancer association with single nucleotidepolymorphisms of RAD51, XRCC2 and XRCC3 genes. Polymorphisms selected in this study were RAD51 135G/C,XRCC2 Arg188His; and XRCC3 Thr241Met. Each polymorphism was genotyped using Polymerase chainreaction-restriction fragment length polymorphism in study cohort of 306 females (156 breast cancer patientsand 150 controls). We observed that heterozygous variant genotype (GC) of RAD51 135 G/C polymorphism wasassociated with a significantly (OR=2.70; 95%CI (0.63-1.79); p<0.03) increased risk of breast cancer. In caseof the XRCC3 gene we observed that frequency of heterozygous (OR=2.88; 95%CI (1.02-8.14); p<0.02) andhomozygous (OR=1.46; 95%CI (0.89-2.40); p<0.04) genotype of Thr241Met polymorphism were significantlyhigher in breast cancer patients. For the Arg188His polymorphism of XRCC2, ~2fold increase in breast cancerrisk (OR=1.6, 95%CI = 0.73-3.50) was associated with GA genotype with a p value for trend of 0.03. Our resultssuggest that the 135G/C polymorphism of the RAD51, Thr241Met polymorphism of XRCC3 and Arg188Hispolymorphism of XRCC2 can be independent markers of breast cancer risk in Pakistan.     

Association of XRCC1 Gene Polymorphisms with Breast Cancer Susceptibility in Saudi Patients

Background: X-ray repair cross-complementing group 1 (XRCC1) plays a key role in the base excision repairpathway, as a scaffold protein that brings together proteins of the DNA repair complex. XRCC1 is reported tobe a candidate influence on cancer risk. The aim of our present study was to assess the association of rs1799782(Arg194Trp) and rs25487 (Arg399Gln) XRCC1 gene polymorphisms with breast cancer in the Saudi population.Materials and Methods: The two SNP’s were analyzed in breast cancer patients and healthy control subjects.Genotypes were determined by TaqMan SNP genotype analysis technique and data were analyzed using Chisquareor t test and logistic regression analysis by SPSS16.0 software. Results and Conclusions: Results showedthat rs1799782 significantly increased susceptibility to breast cancer with Arg/Trp, Arg/Trp+Trp/Trp genotypesand at Trp allele overall study. It also increased risk of breast cancer in older age patients (above 48) and withthe ER positive category. XRCC1rs25487 (Arg399Gln) did not showed any significant association. In conclusionthe XRCC1rs1799782 polymorphism may be involved in the etiology of breast cancer in the Saudi population.Confirmation of our findings in larger populations of different ethnicities is warranted.     

Updated Assessment of the Association of the XRCC1 Arg399Gln Polymorphism with Lung Cancer Risk in the Chinese Population

Background: Published studies have reported relationships between X-ray repair cross-complementing group1 (XRCC1) Arg399Gln polymorphism and lung cancer risk in Chinese population. However, the epidemiologicalresults remained controversial. The objective of this study was to clarify the association of XRCC1 Arg399Glnpolymorphism with lung cancer risk in the Chinese population. Materials and Methods: Systematic searches wereperformed through the database of Medline/Pubmed, Web of Science, Embase, CNKI and WanFang MedicalOnline. Odds ratios (ORs) with 95% confidence interval (95%CI) were calculated to estimate the strength ofthe association. Results: Overall, we observed an increased lung cancer risk among subjects carrying XRCC1codon 399 Gln/Gln genotype (OR=1.36, 95%CI: 1.09-1.71) in the Chinese population on the basis of 19 studieswith 5,416 cases and 5,782 controls. We did not observe any association between XRCC1 codon 399 Arg/Gln andArg/Gln+Gln/Gln polymorphisms and lung cancer risk (OR=1.00, 95%CI: 0.92-1.08 and OR=1.05, 95%CI: 0.97-1.13, respectively). Limiting the analysis to studies with controls in agreement with Hardy-Weinberg equilibrium(HWE), we observed an increased lung cancer risk among subjects carrying XRCC1 codon 399 Gln/Gln genotype(OR=1.18, 95%CI: 1.01-1.38). When stratified by source of control, we observed an increased lung cancer riskamong subjects carrying XRCC1 codon 399 Arg/Gln+Gln/Gln genotype on the basis of hospitalized patient-basedcontrols (OR=1.21, 95%CI: 1.04-1.42) and among subjects carrying XRCC1 codon 399 Gln/Gln genotype onthe basis of healthy subject-based controls (OR=1.22, 95%CI: 1.04-1.43). Conclusions: Our findings indicatedthat certain XRCC1 Arg399Gln variants might affect the susceptibility of lung cancer in Chinese population.Larger sample size studies are required to confirm our findings.     

Polymorphisms of the XRCC1 and XPD Genes and Breast Cancer Risk: A Case-Control Study

The purpose of this case control study was to evaluate the role of X-ray repair cross-complementing group 1 (XRCC1) and xeroderma pigmentosum group D (XPD) genotypes as genetic indicators of susceptibility to breast cancer (BC). We analysed DNA samples from 114 breast cancer patients and 113 control subjects using polymerase chain reaction-restriction fragment length polymorphism. For the single nucleotide polymorphisms in XRCC1 exon 10 (Arg399Gln, G/A) and XPD exon 23 (Lys751Gln, A/C), no remarkable differences for genotype distribution and allele frequencies were observed between BC group and control group in the study. The genotype frequency for homozygote A/A in XPD exon 6 (Arg156Arg, C/A) were significantly different between BC and control groups (P < 0.0001, odds ratio = 2.14; 95% confidence interval 1.44-3.17). The data indicate a possible role for XPD (Arg156Arg, C/A) polymorphisms in BC susceptibility.     

广西扶绥县肝癌家系XRCC1基因Arg399Gln多态性与肝细胞癌的遗传易感性

目的研究广西扶绥县肝癌家系人群DNA修复基因XRCC1Arg399Gln多态性与肝细胞癌（HCC）遗传易感性的相关性。方法采用病例-对照研究方法,对扶绥县21个肝癌家系人群和10个正常家系人群,运用PCR-RFLP方法分析XRCC1基因Arg399Gln位点多态性,并应用Logistic回归模型分析该位点多态性与肝细胞癌遗传易感性的关系。结果通过XRCC1Arg399Gln基因型检测分型,肝癌家系人群携带变异等位基因Gln的频率为23.68%,正常家系人群为13.16%,等位基因在两组间的分布差异无统计学意义（P〉0.05）。基因型分布符合Hardy-Weinberg平衡定律。正常家系人群中携带Arg/Gln者发生HCC的风险是携带Arg/Arg者的1.622倍（95%CI=0.475～5.541,P=0.440）。肝癌家系人群中除肝癌患者外,携带Arg/Gln、Gln/Gln者发生HCC的风险分别是携带Arg/Arg者的1.198倍（95%CI=0.362～3.968）和2.964倍（95%CI=0.434～20.220,P分别为0.768、0.267）。结论广西扶绥县肝癌家系人群中,XRCC1399Arg/Gln基因型和Gln/Gln基因型者患HCC的风险较Arg/Arg基因型者有增加的趋势,但不存在显著相关性。     

XRCC1 polymorphisms and risk of nasopharyngeal carcinoma: a meta-analysis

Objective: Previous studies on the association between X-ray repair cross-complementing protein 1 (XRCC1) polymorphisms and nasopharyngeal carcinoma (NPC) risk showed inconsistent results. The aim of this study was to evaluate the effects of XRCC1 variants on NPC risk. Methods: A meta-analysis was performed with all eligible studies covering a total of 1,341 cases and 1,425 controls for the Arg194Trp polymorphism, 1,260 cases and 1,207 controls for the Arg280His polymorphism, and 1,644 cases and 1,678 controls for the Arg399Gln polymorphism. Results: No associations was found between Arg194Trp and Arg280His polymorphisms with NPC risk under all contrast models (co-dominant, dominant, and recessive models). However a deleterious effect of the 399Gln genotype was observed under the co-dominant model (Gln/Gln versus Arg/Arg, OR = 1.30, 95% CI : 1.01-1.69, P = 0.04). Under the recessive model (Gln/Gln versus Arg/Arg+Arg/Gln), the P value was marginally significant (OR = 1.28, 95% CI : 1.00-1.65, P = 0.05). However, the effect of the 399Gln genotype on NPC became non-significant after excluding one study from the meta-analysis because of departure from Hardy-Weinberg equilibrium. Conclusions: No associations was found between Arg194Trp and Arg280His polymorphisms with NPC risk, whereas the Arg399Gln genotype was associated with increased risk.     

Prognostic Significance of GSTP1, XRCC1 and XRCC3 Polymorphisms in Non-small Cell Lung Cancer Patients

Aim: Individual differences in chemosensitivity and clinical outcome in non-small cell lung cancer (NSCLC)patients treatment with platinum-based chemotherapy may be due to genetic factors. Our study aimed toinvestigate the prognostic role of GSTP1, XRCC1 and XRCC3 in NSCLC patients treated with chemotherapy.Methods: A total of 460 cases were consecutively selected from The Affiliated Hospital of Nantong Universitybetween Jan. 2003 to Nov. 2006, and all were followed-up until Nov. 2011. Genotyping of GSTP1 Ile105Val, XRCC1Arg194Trp, XRCC1 Arg399Gln and XRCC3 Thr241Met was conducted by duplex polymerase-chain-reactionwith confronting-two-pair primer methods. Results: Patients with GSTP Val/Val exhibited a shorter survivaltime, and had a 1.89 fold greater risk of death than did those with the IIe/IIe genotype. For XRCC1 Arg194Trp,the variant genotype Trp/Trp was significantly associated with a decreased risk of death from NSCLC whencompared with the Arg/Arg. Individuals carrying XRCC1 399Gln/Gln genotype had a longer survival time,with a lowered risk of death from NSCLC. Conclusion: This study indicated that GSTP1 Ile105Val, XRCC1Arg194Trp and XRCC1Arg399Gln genes have a role in modifying the effect of platinum-based chemotherapyfor NSCLC patients in a Chinese population. Our findings provide information for therapeutic decisions forindividualized therapy in NSCLC cases.